Clinical Trials Directory

Trials / Completed

CompletedNCT02076906

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Safety and Feasibility Study of Using MR-guided High Intensity Focused Ultrasound (HIFU) for the Ablation of Relapsed or Refractory Pediatric Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
7 (actual)
Sponsor
AeRang Kim · Academic / Other
Sex
All
Age
30 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if Magnetic Resonance guided High Intensity Focused Ultrasound ablative therapy is safe and feasible for children, adolescents, and young adults with refractory or relapsed solid tumors.

Detailed description

Magnetic Resonance (MR)-guided high intensity focused ultrasound (HIFU) is an innovative technique that allows for non-invasive thermal ablation of tissue. Advantages over conventional local tumor control such as surgery, radiation, or radiofrequency are that MR-HIFU is completely non-invasive, non-ionizing, and enables ablation of large tumor volumes with avoidance of adjacent tissue injury. This study will evaluate the safety and feasibility of MR-HIFU ablative therapy in children, adolescents, and young adults with refractory or relapsed solid tumors that are located in bone or soft tissue in close proximity to bone. Patients ≤ 30 years of age with refractory or relapsed solid tumors with measurable target lesions that are located in bone or soft tissue in close proximity to bone are eligible. Tolerability will be defined during the 14 days following MR-HIFU ablation. Patients will continue to be followed for tumor response and secondary outcomes for up to one year post ablation treatment.

Conditions

Interventions

TypeNameDescription
DEVICEMagnetic Resonance High Intensity Focused UltrasoundMR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.

Timeline

Start date
2014-04-01
Primary completion
2021-12-27
Completion
2024-11-24
First posted
2014-03-04
Last updated
2025-01-01

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02076906. Inclusion in this directory is not an endorsement.